|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-1 accelerates autocrine growth of myeloma cells through
interleukin-6 in human myeloma
M Kawano, H Tanaka, H Ishikawa, M Nobuyoshi, K Iwato, H Asaoku, O Tanabe and A Kuramoto
Department of Internal Medicine, Hiroshima University, Japan.
Recombinant interleukin 1 alpha (rIL-1 alpha) augmented proliferation of
freshly isolated myeloma cells as well as B-cell stimulatory factor 2
(BSF-2)/interleukin-6 (IL-6). Recombinant IL-1 alpha-induced proliferation
was partially inhibited by anti-IL-6 antibody. In the culture supernatants
of rIL-1 alpha-stimulated myeloma cells, IL-6 activities, which were
measured by using an IL-6-dependent murine hybridoma clone, MH60.BSF2, were
increased, when compared with those in the culture supernatants of
nonstimulated myeloma cells. Furthermore, IL-6 messenger RNA (mRNA)
expression was also augmented in IL-1 alpha- stimulated myeloma cells.
Therefore rIL-1 alpha stimulates myeloma cells to produce IL-6, which
consequently augments proliferation of myeloma cells. Thus, IL-1 can
accelerate autocrine growth of myeloma cells through IL-6.
Volume 73,
Issue 8,
pp. 2145-2148,
06/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. P. Lagmay, W. B. London, T. G. Gross, A. Termuhlen, N. Sullivan, A. Axel, B. Mundy, M. Ranalli, J. Canner, P. McGrady, et al.
Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma: rs1800795 (Promoter) and rs8192284 (Receptor)
Clin. Cancer Res.,
August 15, 2009;
15(16):
5234 - 5239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Yeh and J. R. Berenson
Treatment for myeloma bone disease.
Clin. Cancer Res.,
October 15, 2006;
12(20):
6279s - 6284s.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Yanamandra, N. M. Colaco, N. A. Parquet, R. W. Buzzeo, D. Boulware, G. Wright, L. E. Perez, W. S. Dalton, and D. M. Beaupre
Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion-Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia
Clin. Cancer Res.,
January 15, 2006;
12(2):
591 - 599.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Abroun, H. Ishikawa, N. Tsuyama, S. Liu, F.-J. Li, K.-i. Otsuyama, X. Zheng, M. Obata, and M. M. Kawano
Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor {alpha}
Blood,
March 15, 2004;
103(6):
2291 - 2298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Sezer, U. Heider, I. Zavrski, C. A. Kuhne, and L. C. Hofbauer
RANK ligand and osteoprotegerin in myeloma bone disease
Blood,
March 15, 2003;
101(6):
2094 - 2098.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Abe, K. Hiura, J. Wilde, K. Moriyama, T. Hashimoto, S. Ozaki, S. Wakatsuki, M. Kosaka, S. Kido, D. Inoue, et al.
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma
Blood,
August 28, 2002;
100(6):
2195 - 2202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Berenson, J. J. Crowley, T. M. Grogan, J. Zangmeister, A. D. Briggs, G. M. Mills, B. Barlogie, and S. E. Salmon
Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients
Blood,
May 1, 2002;
99(9):
3163 - 3168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. D. Roodman
Biology of Osteoclast Activation in Cancer
J. Clin. Oncol.,
August 1, 2001;
19(15):
3562 - 3571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. De Vos, G. Couderc, K. Tarte, M. Jourdan, G. Requirand, M.-C. Delteil, J.-F. Rossi, N. Mechti, and B. Klein
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays
Blood,
August 1, 2001;
98(3):
771 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-H. Han, S. J. Choi, N. Kurihara, M. Koide, Y. Oba, and G. D. Roodman
Macrophage inflammatory protein-1{alpha} is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor {kappa}B ligand
Blood,
June 1, 2001;
97(11):
3349 - 3353.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Blood,
January 15, 2001;
97(2):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Clark, A. J. Flory, E. M. Ion, B. E. Woodcock, B. H. Durham, and W. D. Fraser
Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma
Blood,
October 15, 2000;
96(8):
2697 - 2702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Choi, J. C. Cruz, F. Craig, H. Chung, R. D. Devlin, G. D. Roodman, and M. Alsina
Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
Blood,
July 15, 2000;
96(2):
671 - 675.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Barton, J. Cullison, J. Jackson, and T. Murphy
A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice
Experimental Biology and Medicine,
February 1, 2000;
223(2):
190 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T. A. Guise and G. R. Mundy
Cancer and Bone
Endocr. Rev.,
February 1, 1998;
19(1):
18 - 54.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
T Kishimoto, S Akira, and T Taga
Interleukin-6 and its receptor: a paradigm for cytokines
Science,
October 23, 1992;
258(5082):
593 - 597.
[Abstract]
[PDF]
|
|
|
|
|
